相关实验视频

Updated: Jul 9, 2025

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

了解基因编辑造血干细胞产品中的遗传异质性

Hans Jiro Becker¹, Satoshi Yamazaki¹

¹Laboratory for Stem Cell Therapy, Faculty of Medicine, Tsukuba University, Tsukuba, Japan; Division of Cell Regulation, Center of Experimental Medicine and Systems Biology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Experimental hematology

|November 30, 2023

概括

对于造血干细胞 (HSC) 的CRISPR/Cas基因编辑产生了意想不到的遗传突变. 本综述探讨了这些不受欢迎的编辑的来源和控制它们的策略,以获得更安全的基因疗法.

科学领域:

生物技术是生物技术.
遗传学遗传学是一个
分子生物学分子生物学

背景情况:

基因编辑的CRISPR/Cas技术彻底改变了遗传研究和治疗方法.
造血干细胞 (HSC) 是基因疗法的关键目标.

研究的目的:

审查CRISPR/Cas基因编辑HSC中不必要编辑的来源.
讨论缓解和控制这些意外突变的策略.

主要方法:

关于CRISPR/Cas基因编辑结果在HSC中的科学文献的综述.
对导致遗传变异的细胞通路的分析.
对控制基因编辑忠实性的策略的评估.

主要成果:

CRISPR/Cas编辑通常会导致所需编辑的小子集.
不想要的结果包括插入/删除 (indels) 和染色体重排.
编辑的HSC种群中的遗传异质性可能会降低治疗疗效.

结论:

不需要的突变在临床基因编辑应用中引发了安全问题.
控制基因异质性对于有效的基因疗法至关重要.
需要进一步的研究来优化CRISPR/Cas编辑在HSCs.

更多相关视频

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

Isolation Method for Long-Term and Short-Term Hematopoietic Stem Cells

Isolation Method for Long-Term and Short-Term Hematopoietic Stem Cells

Published on: May 19, 2023

相关概念视频

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

Multipotency of Hematopoietic Stem Cells

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...

Embryonic Stem Cells

Embryonic Stem Cells

Embryonic stem (ES) cells were first discovered in mice in 1981 by Martin Evans. In 1998, James Thomson identified a method to isolate embryonic stem cells from humans. Human embryonic stem cells (hESCs) are obtained from 3-5 day old embryos that remain unused after an in vitro fertilization procedure.
ES cells are grown in a culture medium where they can divide indefinitely, creating ES cell lines. Under certain conditions, ES cells can differentiate, either spontaneously into a variety of...